CGEM ▼ -1.7% - Cullinan Therapeutics, Inc. $CGEM - Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer Cullinan Therapeutics announced it will host a virtual event to present Phase 3 REZILIENT3 data for its zipalertinib plus chemotherapy combination, which was showcased at the IASLC 2026 World Conference on Lung Cancer. The stock declined 1.7% today despite the announcement, suggesting investors may have been disappointed by the trial results or were already pricing in the presentation. 10-SEP-2026 01:00 PM ET